Predict your next investment

Private Equity
whizp.com

See what CB Insights has to offer

Investments

62

Portfolio Exits

19

Funds

16

About Whiz Partners

Whiz Partners, fka CSK Venture Capital, is an alternative asset management firm with private equity, growth equity, venture capital, and global macro hedge fund offerings.

Whiz Partners Headquarters Location

36th Floor, Atago Green Hills MORI TOWER 2-5-1, Atago, Minato-ku

Tokyo, 105-6236,

Japan

+81-(0)3-6430-6778

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Whiz Partners News

Hitachi and Axcelead to start joint development of solutions for the efficient creation of next-generation biopharmaceuticals

Apr 7, 2021

TOKYO, Apr 7, 2021 – (JCN Newswire) – Hitachi, Ltd. (TSE:6501) and Axcelead, Inc. today announced a comprehensive collaborative partnership to develop solutions contributing to the efficient creation of next-generation biopharmaceuticals with digital technology and a drug discovery platform. Hitachi has also invested in the Drug Discovery Gateway Fund (“DDG Fund”) managed by Whiz Partners Inc. (President: Atsushi Matsumura, “Whiz”). Axcelead is a flagship portfolio company of the DDG Fund. With continuous progress of life science, practical applications of next-generation biopharmaceuticals with new therapeutics modalities(1) demonstrating better balance of efficacy and side-effect, such as genes-, cell-, and mRNA(2)- therapeutics, have been recognized. Those new drug discovery modalities are also contributing to the speedy and variety development of vaccines and therapeutics for COVID-19. On the other hand, next-generation biopharmaceuticals are more expensive to develop and manufacture than low-molecular-weight pharmaceuticals, and due to their nature, the product stability and effective period and product life are shorter, and it would be better to develop and manufacture products with small quantity and high variety. Manufacturing costs and risks tend to be high. Through this collaboration, Hitachi and Axcelead will develop solutions that support the more efficient creation of next-generation biopharmaceuticals with digital technology and drug discovery platforms, and also support entities that participate in this field. In addition, the both companies will jointly promote the development of specialized human resources who are familiar with the development and manufacturing of next-generation biopharmaceuticals. Hitachi, with over 100 years deep experience in manufacturing industry, has provided many companies with variety of solutions utilizing Lumada, which accelerates digital innovation by combining OT, IT, and products. In the field of regenerative medicine, Hitachi provides automated cell culture equipment for iPS cells, cell processing facilities, manufacturing execution systems, biosafety cabinets, etc., to pharmaceutical companies and research institutes according to customer needs. Axcelead is a drug desicovery platform company group, having its core company, Axcelead Drug Discovery Partners, Inc. (“ADDP”), which took over the drug discovery platform business of Takeda Pharmaceutical Co., Ltd. (“Takeda”) and started Japan’s first integrated drug discovery solution provider business in 2017. With the investments from DDG Fund, Axcelead sees the horizontal division of labor of pharmaceutical companies as a business opportunity, and has desided to entered the mRNA therapeutics CDMO(3) busienss, DDS(4) technology development business, and drug development business. Axcelead by themselves are going to build ecosystem in this field. Hitachi and Axcelead aim to contribute to improving QoL (Quality of Life) for human through medical innovation with next-generation biopharmaceuticals. (1) Therapeutics modality: A general term for the mechanism of action, materials, and treatment methods of drugs. (2) mRNA: Abbreviation for messenger RNA, a blueprint for making proteins. It is made from DNA in the cell’s nucleus and is degraded shortly after it is used to make proteins. (3) CDMO (Contract Development Manufacturing Organization): A pharmaceutical contract manufacturing and development organization that is entrusted by a customer and makes into practice on behalf of, which are not only pharmaceutical manufacturing but also development. (4) DDS (Drug Delivery System): A technology aimed at maximizing the effects of drugs and minimizing side effects by controlling the distribution of drugs in the body. About Hitachi, Ltd. Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, is focused on its Social Innovation Business that combines information technology (IT), operational technology (OT) and products. The company’s consolidated revenues for fiscal year 2019 (ended March 31, 2020) totaled 8,767.2 billion yen ($80.4 billion), and it employed approximately 301,000 people worldwide. Hitachi drives digital innovation across five sectors – Mobility, Smart Life, Industry, Energy and IT – through Lumada, Hitachi’s advanced digital solutions, services, and technologies for turning data into insights to drive digital innovation. Its purpose is to deliver solutions that increase social, environmental and economic value for its customers. For more information on Hitachi, please visit the company’s website at https://www.hitachi.com . About Axcelead, Inc. Axcelead is a group of companies that develops a drug discovery platform business centered on ADDP, Japan’s first integrated drug discovery solution provider, which took over Takeda’s drug discovery platform business in 2017. Axcelead, is the flagship portfolio company of DDG Fund, which was jointly established by Whiz and Takeda in 2018, with the aim of promoting the drug discovery ecosystem in Japan, and will make various contributions to healthcare broadly and globally. Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Continue Reading

Whiz Partners Investments

62 Investments

Whiz Partners has made 62 investments. Their latest investment was in Caresyntax as part of their Series B on December 12, 2019.

CBI Logo

Whiz Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/12/2019

Series B

Caresyntax

$45.6M

Yes

12

5/31/2018

Series C

WHILL

$45M

Yes

7

5/7/2018

Seed

Lingxi Technology

$1.09M

Yes

1

11/22/2016

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

7/21/2010

Series B

Subscribe to see more

$99M

Subscribe to see more

0

Date

12/12/2019

5/31/2018

5/7/2018

11/22/2016

7/21/2010

Round

Series B

Series C

Seed

Unattributed

Series B

Company

Caresyntax

WHILL

Lingxi Technology

Subscribe to see more

Subscribe to see more

Amount

$45.6M

$45M

$1.09M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

12

7

1

10

0

Whiz Partners Portfolio Exits

19 Portfolio Exits

Whiz Partners has 19 portfolio exits. Their latest portfolio exit was MicroCHIPS Biotech on July 10, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/10/2018

Merger

$99M

1

8/8/2012

IPO

$99M

Public

4/15/2010

Acquired

$99M

1

5/9/2008

Acq - P2P

Subscribe to see more

$99M

Subscribe to see more

0

3/18/2008

Acq - P2P

Subscribe to see more

$99M

Subscribe to see more

0

Date

7/10/2018

8/8/2012

4/15/2010

5/9/2008

3/18/2008

Exit

Merger

IPO

Acquired

Acq - P2P

Acq - P2P

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

1

1

0

0

Whiz Partners Fund History

16 Fund Histories

Whiz Partners has 16 funds, including Whiz Asia Evolution Fund Investment LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/31/2014

Whiz Asia Evolution Fund Investment LP

Diversified Private Equity

Closed

$125.75M

1

6/30/2012

Whiz Healthcare PE Series 1 LP

Industry Focused

Closed

$68.23M

1

4/1/2007

CSK-VC Sustainability Investment Fund

Multi-Stage Venture Capital

Closed

1

4/1/2007

CSK Group Investment Fund

Subscribe to see more

Subscribe to see more

10

8/31/2006

CSK-VC Technology Innovation Fund

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/31/2014

6/30/2012

4/1/2007

4/1/2007

8/31/2006

Fund

Whiz Asia Evolution Fund Investment LP

Whiz Healthcare PE Series 1 LP

CSK-VC Sustainability Investment Fund

CSK Group Investment Fund

CSK-VC Technology Innovation Fund

Fund Type

Diversified Private Equity

Industry Focused

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Closed

Closed

Subscribe to see more

Subscribe to see more

Amount

$125.75M

$68.23M

$99M

Sources

1

1

1

10

10

Whiz Partners Team

16 Team Members

Whiz Partners has 16 team members, including current Chief Executive Officer, President, Toshio Ando.

Name

Work History

Title

Status

Toshio Ando

Chief Executive Officer, President

Current

Junichi Kajimoto

Chief Financial Officer

Current

Tatsuro Kochi

Chief Compliance Officer

Current

Naoki Iwami

Executive Vice President

Current

Louis Choy

Founding Partner

Current

Name

Toshio Ando

Junichi Kajimoto

Tatsuro Kochi

Naoki Iwami

Louis Choy

Work History

Title

Chief Executive Officer, President

Chief Financial Officer

Chief Compliance Officer

Executive Vice President

Founding Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.